Faron jumps as CEO indicates Traumakine study has secured third-party financing
In an interview with Proactive, Dr Markku Jalkanen indicated that the firm had “an understanding that we have third-party financing for the trial”
Company
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
417 stories · page 3 of 5
In an interview with Proactive, Dr Markku Jalkanen indicated that the firm had “an understanding that we have third-party financing for the trial”
Following a meeting with the Food & Drug Administration, the company’s treatment of patients with its interferon-beta (IFN-beta) medication Traumakine will exclude the overlapping use of steroids
Clevegen has been designed to target a range of solid tumours and people with colorectal cancer have previously received it
Patients with late-stage colorectal cancer will be offered Faron drug Clevegen
“Faron considers Rentschler to have otherwise breached the agreement,” the company said in a statement.
According to chief executive Dr Markku Jalkanen, the Faron treatment could finally offer “a biological rationale to guide combination therapies"
The Food & Drug Administration has paved the way for a phase I/II study of the company's Clevegen drug Stateside
This provides investors in the company’s native Finland, many of whom backed the last fundraiser, to trade shares on a local exchange
Archive
A look back at some of the more interesting stories from the junior market this past week...
The £7.48mln raised will be used to initiate part-two of the phase I/II MATINS trial of the Clevegen in colorectal cancer
The biotech saw its shares jump 14.9% to 205p in mid-afternoon trading on Friday
The biopharma firm said its Clevegen treatment could potentially induce a "stronger immune response" at lower doses, increasing its safety margins
The manufacturing process for its lead drug candidate requires "significant" upgrade to receive approval by the authorities
Clevegen is one of two drug candidates being developed by Faron. The other is Traumakine for a condition called acute respiratory distress
Clevegen is precision cancer immunotherapy and information from the MATINS trial will be showcased at the European Society of Medical Oncology Congress, in Barcelona from September 27
The cash injection will provide the group with working capital out to the first quarter of next year
The cash will allow the company to continue clinical development of its lead cancer drug and provide working capital while a partner is sought
The group plans a subscription and open offer of new stock
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Nine patients have been dosed so far with Clevegen, a new type of immune-oncology drug
Investments and investor services
The FTSE 250 went the other way and gained over 87 points on Friday
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at the day's major movers, including 88 Energy, Two Shields, Inland Homes, Avingtrans, Creightons, RM2 and RPS Group
The ratio of the treatment arm versus placebo was two to one and mortality was assessed for a period of 30 days after surgery.
Archive
Bitcoin is up more than 10% but the shine has come off gold a bit
Investments and investor services
A look at the day's major movers, starting with Shearwater, BlueRock, Frontier Smart Technologies, Science Group, MyCelx, Immotion, Biome and Cerillion
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Faron expects to receive the interim results from the INFORAAA study of Traumakine in the near future, allowing a full review of all the Traumakine data with key opinion leaders, after which Faron will make the final decisions on Traumakine
Investments and investor services
The UK's index of leading company shares closed Friday down nearly 23 points at 7,345
Archive
The day ahead includes full-year results from Wizz Air and Charles Stanley
Archive
The shortened trading Week Ahead will only bring updates from the likes of second-liners FirstGroup, Pennon, Wizz Air, and Daily Mail & General Trust
Yrjö Wichmann is stepping down as CFO to become Faron’s new Vice President, Financing and Investor Relations, and he will be replaced by Toni Hänninen
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's major movers, including Tricorn, Eagle Eye, Microsaic, Red Emperor, N4 Pharma, Greggs and Edenville Energy
The company said Timo Syrjälä and Acme Investments SPF Sarl, an entity wholly owned by Syrjälä has subscribed for 1,757,375 new ordinary shares at a price of €0.7598 (£0.65) each
Investments and investor services
On Wall Street, the Dow Jones Industrial Average is up 287 points at the time of writing
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Traumakine disappointed in a late-stage ARDS study last year, but further analysis of the data showed that the drug was effective in certain patients, so another trial is in the works
Investments and investor services
Stock markets in Europe have suffered severe declines as US-China trade tensions have heightened
Archive
The week ahead includes updates from BT Group, Superdry, Morrisons, ITV, IAG, Barratt Developments, Direct Line, RSA Insurance and Imperial Brands
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A look at some of the biggest risers and fallers in London on Monday
Chief executive Dr Markku Jalkanen pointed out: “It appears likely that corticosteroid use diminished the treatment benefit of Traumakine in ARDS patients in the Japanese Phase III study."
It comes after latest data showed that core inflation in the US was flat last month (March) while consumer spending rose
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at the day's major movers, including Vast Resources, Cyanconnode, Trackwise, Mosman, UKOG, 7digital, Scapa and easyHotel
Faron has recruited four people to its trial, and although all of them have reacted well to the drug so far, the colorectal cancer patient has seen the most dramatic response
Investments and investor services
A look at the day's major movers, including Quartix, LiDCO, Convatec, PPHE, Boku and Coral Products
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The AIM-listed clinical-stage biopharmaceutical company said 864,164 shares were placed at a price of 60.0p each with institutional investors after an accelerated bookbuild process
Archive
The UK's premier index closed up nearly 19 points at 7,169, while FTSE 250 added over 96 at 8,896
The first two patients dosed showed marked increases in natural killer (NK) cells and T-Cells
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at the day's major movers, including Gulf Marine Services, Argos Resources, Premier Technical Services, Serco, Vitec, Purplebricks and Centrica
There were noticeable increases in the body’s natural killer cells in the first two patients treated
Faron is currently taking Clevegen through its first in-human clinical trial, and research from a university in Finland has shown that blocking a cell receptor called Clever-1 can suppress tumours
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the top risers and fallers in London on Wednesday
It has carried out a study involving 50 people which has shown its drug was formulated appropriately when administered in a phase III clinical trial
The UK's premier share index finished over 64 points higher at 6,765
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the biggest risers and fallers in London on Wednesday
Analysis of the phase III trial data suggests that ARDS patients with a certain genetic mutation responded particularly well to Traumakine
Archive
FTSE 250 was also down - closing around 58 points lower at 18,271
Archive
A look at some of the London market's biggest risers and fallers on Monday
Archive
A look back at some of the more interesting from the junior market this week...
"At this stage, it appears possible that unexpectedly high corticosteroid use in the INTEREST trial may have masked the treatment benefit of Traumakine in ARDS patients," said Dr Matti Karvonen, the chief medical officer of Faron
Context is everything when it comes to junior drugs stocks. However, the reaction to failure tends to be binary
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the biggest risers and fallers in the London market Monday
FTSE 100 closed down nearly two points on the day at 7,302
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the top risers and fallers in London on Thursday
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
The UK benchmark index of leading shares finished down nearly 32 points at 7,281
Clever-1 is a cell surface receptor shown to control a certain form of immunity
Investments and investor services
The supermarket is the likely standouts in Thursday's market diary.
A look at some of the top risers and fallers in London on Wednesday
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Clever-1 is a cell surface receptor shown to control cell-mediated immunity
The UK blue chip index rose 34 points to 7,308 around 3.40pm
Archive
The week ahead includes annual results from Wetherspoons, Galliford Try and Dunelm along with interims from Morrisons and trading updates from AB Foods and Ashtead
Investments and investor services
This week's round-up looks at the unforgiving nature of the investing public
A look at some of the top risers and fallers in London today
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The company used its Composite Human Antibody platform to enhance the drug
Investments and investor services
Sterling's fall was good news for the Footsie's many big dollar earners
Archive
A look at some of the top risers and fallers in London today
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
“We are very encouraged to find out about the good safety profile of our wholly-owned asset Clevegen," said Faron Pharmaceuticals chief executive Dr Markku Jalkanen
FTSE 250 closed also lower - just shy of 160 points lower at 20,684, while FTSE small cap market shed around 25 points
Some of the main news-driven risers and fallers in London on Thursday afternoon...
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
It has discovered that a sub-group of patients with higher levels of certain bio-markers showed a reduced mortality rate and increased ventilator-free days
Investments and investor services
The FTSE 100 has clawed back all of this morning's losses and some, while the ECB has unveiled plans to end its quantitative easing programme in December
Archive
A glance at some of the day's highlights from the Proactive Investors newswire